An Open-label, Multiple-dosing, Crossover, and Parallel Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers

NCT00923533 Phase 1 COMPLETED

To evaluate drug-drug interaction between fimasartan and hydrochlorothiazide.

Details

Lead sponsor	Boryung Pharmaceutical Co., Ltd
Phase	Phase 1
Status	COMPLETED
Enrolment	34
Start date	2009-03
Completion	2009-08

Conditions

• Essential Hypertension

Interventions

• Fimasartan
• Hydrochlorothiazide

Primary outcomes

• AUC, Cmax, Tmax, CL/F — 0, 0.5, 1, 1.5, 2, 2.5 3, 4, 6, 8, 12, 24 hours at 7 day and 21 day